Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma
Exelixis Announces CELESTIAL Phase 3 Pivotal Trial Results Published in The New England Journal of Medicine
RUA GOLD Begins Drilling at Cumberland Target in the Reefton Goldfield, Following up on a 20.7m Intercept of 62g/t Gold
